Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.
Develops next-generation peptide immunotherapy platform using AI metagenomics and high-throughput profiling to engage memory T cells for cancer and autoimmune diseases